* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:LKFT vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV (WBO:LKFT) has a FCF Margin % of -1,278.71% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lakefront Biotherapeutics NV and its competitors. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #386 out of 959 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Lakefront Biotherapeutics NV's FCF Margin % too high?
Lakefront Biotherapeutics NV's current FCF Margin % is -1,278.71%. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #386 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #386 out of 959 companies for FCF Margin %. This puts Lakefront Biotherapeutics NV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current FCF Margin % is -1,278.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (WBO:LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is €104.25, compared to a current price of €25.50 — trading 75.5% below its estimated fair value. The current FCF Margin % is -1,278.71%. Lakefront Biotherapeutics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (WBO:LKFT), the current FCF Margin % is -1,278.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (WBO:LKFT) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of €25.50 is trading 75.5% below its estimated GF Value™ of €104.25.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for WBO:LKFT:
FCF Margin %: -1,278.71%
GF Value™: €104.25 vs. price of €25.50 (75.5% below fair value)
No single metric tells the full story. See the WBO:LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
60GF Score
Get the complete analysis for WBO:LKFT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:LKFT has been successfully added to your 
